

Gibson Dunn Advises Arrowhead Pharmaceuticals on Establishing “At the Market” Facility for Sale of up to \$500 Million of Common Stock

Firm News | December 11, 2025

Gibson Dunn represented Arrowhead Pharmaceuticals, Inc. on establishing an "at the market" facility for the sale of up to \$500 million of its common stock. Arrowhead is a biotechnology company developing medicines that treat intractable diseases by silencing the genes that cause them.

Gibson Dunn regularly advises life sciences companies on capital markets transactions, including at-the-market offerings and equity financings.

The Gibson Dunn team included Ryan Murr, Melanie Neary, and Lauren Navarro.

Related People

[Ryan A. Murr](#)

[Melanie E. Neary](#)

[Lauren Navarro](#)

Related Capabilities

[Capital Markets](#)

[Life Sciences](#)